The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Unless otherwise indicated, references to the "Company," "us" or "we" refer to Hestia Insight Inc. and its subsidiaries.

Special Note Regarding Forward-looking Statements

All statements other than statements of historical fact included in this Form 10-K including, without limitation, statements under "Management's Discussion and Analysis of Financial Condition and Results of Operations" regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. When used in this Form 10-K, words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to us or our management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including those set forth under the risk factors and business sections in this Form 10-K.





Overview


Hestia Insight Inc. ("Hestia", "Hestia Insight", or the "Company") was incorporated in the State of Nevada on November 19, 2003, under the name Luxshmi Investments, Inc. ("Luxshmi Investments"), until the Company changed its name to Hestia Insight Inc. on March 27, 2019. On March 12, 2019, the Company filed a Certificate of Amendment to its Articles of Incorporation authorizing 300,000,000 shares of capital stock, comprised of 290,000,000 shares of common stock, par value $0.001 per share (the "Common Stock") and 10,000,000 shares of preferred stock, par value $0.00001 per share (the "Preferred Stock"). On March 27, 2019, the Company filed a Certificate of Amendment to its Articles of Incorporation (i) effecting a name change from Luxshmi Investments, Inc. to Hestia Insight Inc., and (ii) effecting a 50-to-1 reverse stock split of the Company's issued and outstanding shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split did not impact the Company's authorized shares of Common Stock or Preferred Stock, or its par value. On May 16, 2019, the Company entered into a Share Exchange Agreement with Hestia Investments Inc., a Wyoming corporation ("Hestia Investments"), to exchange, on a 1-for-1 basis, 27,614,200 shares of the Company's Common Stock in exchange for 27,614,200 shares of Hestia Investments which were owned by 100% of the then-shareholders of Hestia Investments (the "Share Exchange Transaction"). As a result of the Share Exchange Transaction, Hestia Investments became a wholly owned subsidiary of the Company.

The Company is focused primarily on the healthcare and biotech sectors through the Company's two wholly owned operating subsidiaries, Hestia Investments Inc. ("Hestia Investments"), and HSTA HEALTH INC., d/b/a Hestia Vending ("Hestia Vending"). Hestia Investments provides strategic consulting, medical supply sales and marketing support, management, and capital markets advisory services for select micro, small and medium sized companies within the healthcare and biotech sectors. Hestia Vending operates within the healthy food, beverage and wellness products industry and the smart vending machine industry. The Company is positioned to make strategic acquisitions of emerging growth companies with unique sciences and technologies. The Company intends to pursue the acquisition and development of healthcare related technologies in the healthcare and biotech sectors through acquisition, licensing, or joint ventures. The Company will also consider a third avenue of investing in certain technologies. The Company entered the healthcare sector to explore emerging healthcare technologies, especially growth companies that own and develop unique sciences and technologies.





                                       15





Our Markets and Services



The Company's wholly owned operating subsidiary, Hestia Vending, operates within the healthy food, beverage and wellness products industry and the smart vending machine industry. On July 11, 2022, Hestia Vending entered into a Vending Purchase Agreement with HealthyYOU Vending LLC ("HealthyYou") pursuant to which the Company purchased from HealthyYou ten (10) fully automated vending machines and related equipment (the "Vending Machines") for an aggregate purchase price of $98,745.00, in connection with the Company's vending pilot program. The technologically advanced, unattended Vending Machines dispense healthy food and wellness products to paying customers at the point of sale, accepting cash, coin, credit or debit cards, and payments by smartphones, watches and other devices. The Company's goal is to create a technology-driven health and wellness vending business division through its purchase and operation of the Vending Machines. In addition, on September 24, 2022, Hestia Vending entered into a strategic partnership with ChargerGoGo, Inc. ("ChargerGoGo"), a Las Vegas-based company which operates one of the largest portable phone charging networks in the US. Hestia Vending plans to introduce ChargerGoGo smart phone charging station and power bank kiosks in densely populated locations and venues for smart phone charging convenience. ChargerGoGo smart phone charging station and power banks allow users to obtain a portable battery from any ChargerGoGo kiosk, charge their smart phones, and avoid missing an important event or meeting. ChargerGoGo portable batteries are then returned by users to any nearby ChargerGoGo kiosk.

The Company is positioned to make strategic acquisitions of and enter joint ventures with emerging growth companies with unique sciences and technologies. The Company also provides sales and marketing guidance and services and capital markets advisory services to its clients.





Sales and Marketing


We seek to develop new business through relationships driven by our senior management, which have extensive contacts throughout the healthcare system. Our senior management is seeking opportunities for joint ventures, strategic relationships and acquisitions in the healthcare and biotech sectors.





Business Model


The Company intends to pursue the acquisition and development of healthcare related technologies in the healthcare and biotech sectors through acquisition, licensing or joint ventures. We will also consider a third avenue of investing in certain technologies. The Company entered the healthcare sector to explore emerging healthcare technologies, especially growth companies that own and develop unique sciences and technologies.





Competitive Advantages


The Company focuses on small and micro-cap companies in the healthcare and biotech sectors with limited access to growth capital. We provide specialized consulting services to assist companies with their operations in the public markets. Our management team is experienced in risk management and exit planning. The Company's competitive advantages include a global business network of healthcare, investment and financial professionals who are integrated into the technology licensing and commercialization departments of universities and institutions. Through our offered services and access to investment, we intend to accelerate the development and commercialization of the healthcare businesses that we engage with.





Strategic Relationships



Noether Sciences and Technologies, Inc. On November 18, 2020, the Company entered into a non-binding Supplemental Agreement of Memorandum of Understanding (the "Noether MOU") with Noether Science and Technologies, Inc. ("NSAT") pursuant to which the parties will seek to enter into a definitive agreement to (i) establish an exclusive partnership that will focus on research and treatment of neurological and psychiatric disorders, (ii) commercialize existing NSAT technologies for the healthcare market, (iii) provide the Company with an exclusive license to use and develop the existing and ready to use depression and anxiety therapy protocols in the United States, and (iv) establish a neurotherapy center in the metropolitan New York City area and another 3-4 clinics in other strategic areas yet to be determined.

Immudyne Nutritional. On June 21, 2020, the Company entered into a sales agency agreement with Immudyne Nutritional LLC ("Immudyne"), pursuant to which the Company acts as sales agent for certain of Immudyne's medical products. Immudyne is located in Jacksonville, Florida.

We are in negotiation in our areas of focus with respect to potential acquisitions and strategic partnerships. There is no guarantee that we will be able to successfully sign a definitive agreement, close or implement such business arrangement.





                                       16





Going Concern


We have a limited operating history and our continued growth is dependent upon the continuation of providing medical consulting services to our clients, generating revenue, and obtaining additional financing to fund future obligations, and pay liabilities arising from normal business operations. We had accumulated deficits of $(256,123) at November 30, 2022. The report of our independent registered public accounting firm on our financial statements for the year ended November 30, 2022, contained an explanatory paragraph regarding our ability to continue as a going concern based upon cash used in operating activities and the current cash balance cannot be projected to cover the operating expenses for the next twelve months from the release date of this report. These factors, among others, raised substantial doubt about our ability to continue as a going concern. Our financial statements appearing elsewhere in this report do not include any adjustments that might result from the outcome of this uncertainty. There are no assurances we will be successful in our efforts to generate significant revenues or report profitable operations or to continue as a going concern, in which event investors would lose their entire investment in our company. The financial statements contained herein do not include any adjustments that might result from the outcome of this uncertainty.

Our ability to continue as a going concern is dependent upon our ability to carry out our business plan, achieve profitable operations, obtain additional working capital funds from our significant shareholders, and or through debt and equity financings. However, there can be no assurance that any additional financings will be available to us on satisfactory terms and conditions, if any.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to bad debts, recovery of long-lived assets, income taxes and the valuation of equity transactions.

We base our estimates on historical experience and on various other assumptions that we believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the consolidated financial statements.





Revenue Recognition


We recognize revenue when persuasive evidence of an arrangement exists, delivery has occurred or products have been sold, the purchase price is fixed or determinable and collectability is reasonably assured.

We provide medical related consulting services to our clients. We are paid fees for our services by our clients under written consulting agreements. Each contract calls for a fixed payment in a fixed period of time. We recognize revenue by providing medical related consulting services under written service contracts with our customers. Revenue related to our service offerings is recognized as the services are performed and amounts are earned, using the straight-line method over the term of the related services agreement. Prepayments, if any, received from customers prior to the services being performed are recorded as advance from customers. In these cases, when the services are performed, the amount recorded as advance from customers is recognized as revenue.





Income Taxes


We are governed by the income tax laws of the United States. Income taxes are accounted for pursuant to ASC 740 "Accounting for Income Taxes," which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. The charge for taxes is based on the results for the period as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

Deferred tax is accounted for using the balance sheet liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences, and deferred tax assets are recognized to the extent that it is probably that taxable profit will be available against which deductible temporary differences can be utilized.

Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is changed to equity. Deferred tax assets and liabilities are offset when they related to income taxes levied by the same taxation authority and we intend to settle its current tax assets and liabilities on a net basis.





                                       17





Stock-based Compensation


Stock based compensation is accounted for based on the requirements of the Share-Based Payment topic of Accounting Standards Codification ("ASC") 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award. The Accounting Standards Codification also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the "measurement date." The expense is recognized over the period of services or the vesting period, whichever is applicable. Until the measurement date is reached, the total amount of compensation expense remains uncertain. We record compensation expense based on the fair value of the award at the reporting date. The awards to consultants and other third-parties are then revalued, or the total compensation is recalculated based on the then current fair value, at each subsequent reporting date.

Recent Accounting Pronouncements

In August 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This ASU addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. This ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years, with early adoption permitted. An entity that elects early adoption must adopt all of the amendments in the same period. We are currently evaluating the impact it may have on our consolidated financial statements.

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption. We do not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to our consolidated financial condition, results of operations, cash flows or disclosures.





RESULTS OF OPERATIONS



Comparison of Results of Operations for the Year Ended November 30, 2022, and the Year Ended November 30, 2021.





Revenue


During the year ended November 30, 2022, total revenues amounted to $15,000. For the year ended November 30, 2021, revenue was $28,500 which consisted of $20,000 in consulting revenue and $8,500 in consulting revenue with a related party. The decrease of $13,500 in revenue was due to a decrease in consulting revenue.





Cost of Revenue


Cost of revenue includes the direct cost of internal labor and related benefits, travel expenses related to consulting services, direct subcontractor costs, other related direct consulting costs.

For the years ended November 30, 2022 and 2021, the cost of revenue were $0 and $1,478, respectively, representing a decrease of $1,478. The decrease of cost of revenue was mainly driven by a decrease in the direct costs to produce the revenue.





Operating Expenses



For the years ended November 30, 2022 and November 30, 2021, operating expenses
consisted of the following:



                                    For the Year       For the Year
                                       Ended              Ended
                                    November 30,       November 30,
                                        2022               2021
Selling expense                    $       11,929     $          367
Professional fees                         269,900            217,813
Other general and administrative           81,439             29,037
                                   $      363,268     $      247,217




                                       18





    ?   Our selling expense mainly includes our marketing and sales staff's
        salaries and related benefits, and travel and entertainment costs incurred
        by our sales department. Selling expense totalled $11,929 for the year
        ended November 30, 2022, and $367 for the year ended November 30, 2021.
        This is an increase of  $11,562. Selling expense as a percentage of
        revenue for the year ended November 30, 2022 was 79.5%.




    ?   Professional fees primarily consisted of accounting fees, legal service
        fees, consulting fees, investor relations service charges and other fees
        incurred for service related to becoming and being a public company. For
        the years ended November 30, 2022, and November 30, 2021, professional
        fees amounted to $269,900 and $217,813, respectively, an increase of
        $52,087 or 23%.  There was an increase of $63,996 in expenses paid to
        independent contractors in the United States, an increase of approximately
        $453 in fees and services associated with public company reporting, an
        increase of approximately $28,455in service fees provided by professionals
        in China. These increases are offset by a decrease in legal services of
        $500, a decrease in audit fees of approximately $9,800 and a decrease of
        $2,188 incurred for services performed by our financial consultants and
        others. We expect professional fees to increase as we incur significant
        costs associated with our public company reporting requirements, and costs
        associated with newly applicable corporate governance requirements,
        including requirements under the Sarbanes-Oxley Act of 2002 and other
        rules implemented by the Securities and Exchange Commission.




    ?   Other general and administrative expenses mainly consisted of employee
        compensation, officer compensation, travel and entertainment, office
        supplies, rent, bank service charges and other miscellaneous items. Other
        general and administrative expenses totalled $81,439 for the year ended
        November 30, 2022, as compared to $29,037 for the period year ended
        November 30, 202, an increase of $52,402 or 180%. This increase was
        primarily attributable to an increase in payroll and payroll taxes of
        $34,574, an increase in travel and meals of $11,423, an increase in
        depreciation expense of $6,367 and an increase in other general and
        administrative expenses of $9,065. There was also a decrease in officer's
        compensation of $9,000.



Income (Loss) from Operations

As a result of the foregoing, for the year ended November 30, 2022, loss from operations amounted to $348,268 as compared to loss from operations of $220,195 for the year ended November 30, 2021, an increase of $128,073.





Other Income


Other income includes interest income from bank deposits and loans receivable of $290, interest income on lease receivable of $4,228 and dividend income from our investments in equities of $750; all of which amounted to $5,268 for the year ended November 30, 2022, as compared to $521 for the year ended November 30, 2021.

The Company had realized gains on equity investments of $233,795 for the year ended November 30, 2022, and $140,268 in realized gains for the year ended November 30, 2021.

The Company had unrealized losses on equity investments of $1,594,716 for the year ended November 30, 2022, and $9,687,011 in unrealized losses for the year ended November 30, 2021.





Other expense


The Company incurred interest expense of $0 for the year ended November 30, 2022, and $0 for the year ended November 30, 2021.





Income Taxes


We did not have any income taxes expense for the years ended November 30, 2022, and November 30, 2021.





                                       19





Net Income (Loss)


Net income/(loss) for the years ended November 30, 2022 and 2021 were $(1,713,921) and $(9,766,417), respectively.

Liquidity and Capital Resources

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations and otherwise operate on an ongoing basis. At November 30, 2022 and 2021, we had cash balance of $252,956 and $524,741, respectively. These funds are kept in financial institutions located in United States. We had total liabilities of $34,106 for the year ended November 30, 2022, of which $0 is a loan payable to a related party, and $29,560 for the year ended November 30, 2021, of which $0 is a loan payable to a related party. As of November 30, 2022, and 2021, the Company had accumulated earnings/(deficits) of $(256,123) and $1,457,798, respectively.

We currently have no agreements and arrangements with any person to obtain funds through bank loans, lines of credit or any other sources. Since the Company has no such arrangements or plans currently in effect, its inability to raise funds for the above purposes will have a severe negative impact on its ability to remain a viable company.

Cash flows from Operating Activities

Operating activities used $340,957 in cash for the year ended November 30, 2022, as compared with using $209,703 for the year ended November 30, 2021. These uses of cash from operating activities are mainly the result from a net operating loss of $348,268 for the year ended November 30, 2022 and a net operating loss of $220,195 for the year ended November 30, 2021.

Cash flows from Investing Activities

For the year ended November 30, 2022, the Company's net cash flow provided by investing activities was $223,795, and for the year ended November 30, 2021, the Company's net cash flow provided by investing activities was $140,268.

Cash flows from Financing Activities

For the year ended November 30, 2022, the Company used $154,623 of net cash flow in financing activities, and for the year ended November 30, 2021, the Company used $4,589 of cash flow in financing activities. For the year ended November 30, 2022 the Company used $68,255 to purchase equipment leased to others, $112,563 to purchase vending machines for its operations and received $26,195 from the issuance of common stock. For the year ended November 30, 2021, the Company used $4,589 in a note receivable from others.

Our capital requirements for the next twelve months primarily relate to cash to pay salaries, consulting fees and fees related to third parties' professional services. All funds received have been expended in the furtherance of growing the business. The following trends are reasonably likely to result in a material decrease in our liquidity over the near to long term:





  ? An increase in working capital requirements to finance our current business;




  ? Addition of administrative and sales personnel as the business grows; and




  ? The cost of being a public company.



We will need to raise additional funds, particularly if we are unable to generate positive cash flow as a result of our operations. We estimate that based on current plans and assumptions, that our available cash will be insufficient to satisfy our cash requirements under our present operating expectations. Other than working capital and advance received from related parties and funds received pursuant to securities purchase agreements, we presently have no other significant alternative source of working capital. We have used these funds to fund our operating expenses, pay our obligations and grow our company. We will need to raise significant additional capital to fund our operations and to provide working capital for our ongoing operations and obligations. Therefore, our future operation is dependent on our ability to secure additional financing. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. However, the trading price of our common stock and a downturn in the U.S. equity and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. The inability to obtain additional capital may restrict our ability to grow and may reduce our ability to continue to conduct business operations. If we are unable to obtain additional financing, we will be required to cease our operations. To date, we have not considered this alternative, nor do we view it as a likely occurrence.





                                       20





Going Concern


The Company's financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company incurred a net loss of $1,713,921 for the year ended November 30, 2022, and a net loss of $9,766,417 for the year ended November 30, 2021. The Company had accumulated deficits of $256,123 as of November 30, 2022, and accumulated earnings of $1,457,798 as of November 30, 2021. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.

Off-balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Since inception, our principal sources of operating funds have been proceeds from equity financing including the sale of our Common Stock to initial investors known to management and principal shareholders of the Company. We do not expect that our current cash on hand will fund our existing operations. We will need to raise additional capital in order execute our business plan and growth goals for at least the next twelve-month period thereafter. If the Company is unable to raise sufficient additional funds, it will have to execute a slower than planned growth path, reduce overhead and scale back its business plan until sufficient additional capital is raised to support further operational expansion and growth. There can be no assurance that such a plan will be successful.

© Edgar Online, source Glimpses